300 filings
Page 5 of 15
8-K
vsni0fyori1z
15 Apr 21
Regulation FD Disclosure
1:30pm
CT ORDER
n7vvj
7 Apr 21
Confidential treatment order
12:00am
S-8
60hgrgoit
11 Mar 21
Registration of securities for employees
4:42pm
8-K
cq4ou0vn1t
11 Mar 21
Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates
4:02pm
8-K
vh0f 5vxyxhpsy
1 Mar 21
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:28pm
424B5
mxsttt2y5ybv7nzyqlbz
1 Mar 21
Prospectus supplement for primary offering
5:23pm
8-K
hn0pi mni0sib7r0
26 Feb 21
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
4:41pm
8-K
729lx
12 Feb 21
Entry into a Material Definitive Agreement
5:01pm
8-K
udhlfalsr0r7u7a8d4r
1 Feb 21
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
4:46pm
8-K
0ydn abv1j8ofpynygc
14 Dec 20
Nabriva Therapeutics Announces Proposed Public Offering
4:25pm
424B5
212 mo1wflr5
11 Dec 20
Prospectus supplement for primary offering
5:26pm
424B5
atm1dwviu8
10 Dec 20
Prospectus supplement for primary offering
5:19pm
8-K
wceuuup htllm8h
7 Dec 20
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China
7:30am
8-K
wpdxx3
3 Dec 20
Material Modifications to Rights of Security Holders
6:04am
8-K
mssj4340p 99wdn5ebs
5 Nov 20
Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:06pm
EFFECT
6socmuzg9tecedck1
14 Sep 20
Notice of effectiveness
12:15am
CORRESP
ypol5l
9 Sep 20
Correspondence with SEC
12:00am
UPLOAD
qsc9fs617s
8 Sep 20
Letter from SEC
12:00am